11/2024. Clinical Trial with Birch-Mannan Conjugates

Allergy publishes results of a phase 3 clinical trial of mannan conjugated birch pollen allergoids.

Birch pollen is a major cause of spring respiratory allergy in central and northern Europe. Mannan-conjugated allergoids represent a new generation of vaccines for specific immunotherapy targeting dendritic cells developed by INMUNOTEK.

The Phase 3 clinical trial was conducted in Germany and evaluated the efficacy and safety of birch mannan allergoids administered subcutaneously in a short 5-dose schedule prior to the pollen season. The chosen dose was established in a previous study.

The published results confirm the safety and efficacy of mannan conjugated allergoids in a short regimen.

More information here.